HRD-negative high-grade carcinoma of the ovary in <i>BRCA2</i> pathogenic variant carrier

QR Code

HRD-negative high-grade carcinoma of the ovary in <i>BRCA2</i> pathogenic variant carrier

Background. Homologous recombination deficiency (HRD) is a valuable molecular marker for predicting response to platinum agents and poly(ADP-ribose)-polymerase (PARP) inhibitors. Germline and somatic alterations in the BRCA1 and BRCA2 genes are the major cause of HRD in ovarian cancer. However, in s...

Full description

Saved in:

Bibliographic Details
Main Authors:	A. P. Sokolenko, S. V. Poletaeva, A. D. Shestakova, T. V. Gorodnova, I. V. Berlev, E. N. Imyanitov
Format:	Article
Language:	Russian
Published:	Russian Academy of Sciences, Tomsk National Research Medical Center 2024-05-01
Series:	Сибирский онкологический журнал
Subjects:	<i>brca1</i> and <i>brca2</i> mutations loss of heterozygosity brcaness high-grade ovarian carcinoma homologous recombination deficiency
Online Access:	https://www.siboncoj.ru/jour/article/view/3050
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Features and complexity of treatment of <i>BRCA</i>-associated ovarian cancer, chronic disease: literature review
by: T. V. Gorodnova, et al.
Published: (2024-11-01)

A clinical case of repeat use of PARP inhibitors in a patient with <i>mBRCA</i>-associated ovarian cancer
by: A. B. Villert, et al.
Published: (2022-09-01)

LOSS OF HETEROZYGOSITY IN THE BRCA1 AND BRCA2 LOCUS IN BREAST CANCER
by: M. M. Tsyganov, et al.
Published: (2020-07-01)

Case Report: Clinical impact of BRCA1 and BRIP1 vs. BRCA1 and BRCA2 germline double heterozygosity in ovarian cancer: a comparative case study
by: Limei Zheng, et al.
Published: (2025-07-01)

Prophylactic adnexectomy in BRCA1 and BRCA2 gene mutation carriers (а review of literature)
by: T. A. Shendrikova, et al.
Published: (2014-07-01)

The prognostic significance of BRCA1 gene expression in patients with breast cancer
by: M. M. Tsyganov, et al.
Published: (2019-07-01)

Breast cancer screening in germline mutation carriers. A literature review
by: A. V. Sultanbaev, et al.
Published: (2023-08-01)

Study of the Carrier State for Five BRCA1/BRCA2 Deleterious Mutations in Bulgarian Women with Breast Cancer
by: Katia Kovacheva, et al.
Published: (2013-12-01)

Comparison of risk assessment models of BRCA1 and BRCA2 mutation carrier in patients with breast cancer.
by: L. A. Rybchenko, et al.
Published: (2013-12-01)

Prevalence of <i>BRCA1</i> c.5161C>T mutation in cancer patients from Bashkortostan
by: M. A. Bermisheva, et al.
Published: (2021-12-01)

Current approaches to systemic treatment of <i>BRCA</i>-associated triple-negative breast cancer
by: D. A. Enaldieva, et al.
Published: (2023-10-01)

A systematic review on the association between ovarian and prostate cancer with <I>BRCA1</I> and <I>BRCA2</I> gene
by: Sarpparajan Chitra Veena, et al.
Published: (2023-01-01)

Experience in the use of olaparib poly (ADP-ribose) polymerase inhibitors in maintenance therapy of BRCA-associated ovarian cancer
by: V. N. Zhurman, et al.
Published: (2023-02-01)

Modulation of homologous recombination gene activity in breast tumor cells in an <i>in vitro</i> model
by: M. M. Tsyganov, et al.
Published: (2024-06-01)

Clinical features of BRCA-positive ovarian cancer
by: S. Ya. Maximov, et al.
Published: (2016-02-01)

Role of BRCA 1 и BRCA 2 gene mutations in the occurrence of male breast cancer
by: A. V. Bykova, et al.
Published: (2014-07-01)

Occurrence of BRCA1 and BRCA2 mutation in pancreatic cancer patients
by: A. A. Kashintsev, et al.
Published: (2016-02-01)

BRCA1, BRCA2 mutations — future of predictive oncology: a review of literature
by: V. N. Dmitriev, et al.
Published: (2014-07-01)

Study of the UV Irradiation and Nalidicsic Acid Effect on the RecA-protein Induction in <i>Francisella tularensis</i> 15/10 Cells
by: A. A. Lapin, et al.
Published: (2011-06-01)

A RARE CASE OF MULTIPLE-PRIMARY CANCER IN A WOMAN WITH BRCA 1 GENE MUTATION: BRCA-ASSOCIATED OVARIAN CANCER AND LUNG CARCINOID TUMOR
by: A. О. Ivantsov, et al.
Published: (2018-03-01)

Prevalence of Five BRCA1/2 Mutations in Bulgarian Breast Cancer Patients
by: Katia Kovacheva, et al.
Published: (2019-01-01)

Association of polymorphic markers of the <i>XRCC1</i>, <i>ERCC5</i>, <i>TP53</i>, <i>CDKN1A1</i> genes with the survival of patients after platinum-based chemotherapy for triple negative breast cancer
by: T. M. Zavarykina, et al.
Published: (2023-05-01)

Modern clinical portrait of ovarian cancer patient in the Novosibirsk region
by: A. V. Tarkhov, et al.
Published: (2025-03-01)

Canadian Recommendations for Germline Genetic Testing of Patients with Breast Cancer: A Call to Action
by: Evan Weber, et al.
Published: (2025-05-01)

BRCA1GENE EXPRESSION IN ENDOCRINE TUMORS OF THE GASTROINTESTINAL TRACT
by: I. G. Gafton, et al.
Published: (2016-02-01)

Detection of BRCA1and BRCA2 mutation for Breast Cancer in Sample of Iraqi Women above 40 Years
by: Baghdad Science Journal
Published: (2010-03-01)

Prevalence of germline BRCA1/2 pathogenic variants in unselected Korean patients with HER2-negative metastatic breast cancer: a nationwide prospective study (KCSG BR19-10)Research in context
by: Hee Kyung Ahn, et al.
Published: (2025-07-01)

Significance and possible causes of hormone receptor expression loss in metastatic breast cancer. Phenotypic evolution of luminal <i>BRCA1</i>-associated breast cancer to triple negative subtype in lung metastasis and PARP inhibition strategy in early-line therapy
by: A. I. Stukan, et al.
Published: (2022-12-01)

Tumor immune microenvironment and apoptotic markers in breast cancer patients carrying <I>BRCA1</I> gene mutations
by: A. I. Stukan, et al.
Published: (2022-09-01)

Prognostic Value of BRCA1 and BRCA2 Gene Mutations in Prostate Cancer: a Literature Review
by: M. V. Loginova, et al.
Published: (2021-05-01)

Genotype-phenotype correlations in patients with breast cancer and BRCA1 mutations (4153delA, 185delAG, 5382insC)
by: Ye. M. Bit-Sava, et al.
Published: (2014-07-01)

RISK FACTORS OF OVARIAN CANCER AND POSSIBLE PREVENTIVE STRATEGIES
by: OLGA B. Karelina, et al.
Published: (2018-09-01)

Causes of resistance to PARP inhibitors and ways to overcome it. Case report of aggressive <i>BRCA</i>-related breast cancer
by: A. I. Stukan, et al.
Published: (2022-05-01)

Molecular biological subtypes of breast cancer in BRCA1 mutation carriers
by: N. I. Pospekhova, et al.
Published: (2021-01-01)

Assembly and Analysis of the Mitochondrial Genome of <i>Hippophae rhamnoides</i> subsp. <i>sinensis</i>, an Important Ecological and Economic Forest Tree Species in China
by: Jie Li, et al.
Published: (2025-07-01)

Comparative Evaluation of Recombinant <i>Chlamydia abortus</i> and <i>Chlamydia trachomatis</i> Major Outer Membrane Proteins for Diagnosing Human Chlamydial Infection
by: Fernando M. Guerra-Infante, et al.
Published: (2025-07-01)

Comparative characteristics of the effectiveness of therapy with PARP inhibitor in patients with primary ovarian cancer in the Tyumen Region in the period from 2019 to 2023
by: M. Ya. Kuzmenko, et al.
Published: (2025-05-01)

Characterization and functional analysis of BRCA1 and BRCA2 variants in a cohort of 100 unselected patients undergoing germline screening
by: Qianqian Shi, et al.
Published: (2025-09-01)

CLINICAL AND MORPHOLOGICAL FEATURES OF HEREDITARY OVARIAN CANCER
by: K. B. Kotiv, et al.
Published: (2017-12-01)

Synchronous Metastasizing High-Grade Papillary Serous Carcinoma of the Fallopian Tube and Triple-Negative Primary Breast Cancer in a BRCA1 Mutation Carrier
by: Mihnea-Andrei Nicodin, et al.
Published: (2025-04-01)